CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedMay 30, 2024
DataAggregated Company Financials
Companies195
- 7D-5.9%
- 3M-4.6%
- 1Y-29.2%
- YTD-17.0%
Over the last 7 days, the Healthcare industry has dropped 5.9%, driven by Akeso declining 33%. In contrast, CSPC Pharmaceutical Group has gained 6.1%. However, the industry is down 29% over the past year. Looking forward, earnings are forecast to grow by 24% annually.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 30 May 2024 | HK$1.3t | HK$1.4t | HK$28.6b | 12.2x | 45x | 0.9x |
| Sat, 27 Apr 2024 | HK$1.3t | HK$1.4t | HK$28.7b | 11.6x | 46.9x | 0.9x |
| Mon, 25 Mar 2024 | HK$1.3t | HK$1.4t | HK$28.1b | 11.6x | 47x | 0.9x |
| Wed, 21 Feb 2024 | HK$1.3t | HK$1.4t | HK$27.1b | 11.5x | 48.4x | 0.9x |
| Fri, 19 Jan 2024 | HK$1.4t | HK$1.4t | HK$25.9b | 11.6x | 54.5x | 1x |
| Sun, 17 Dec 2023 | HK$1.6t | HK$1.4t | HK$26.5b | 13.1x | 59.2x | 1.1x |
| Tue, 14 Nov 2023 | HK$1.6t | HK$1.4t | HK$25.0b | 12.8x | 65.7x | 1.2x |
| Thu, 12 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.6b | 12.2x | 64.9x | 1.1x |
| Sat, 09 Sep 2023 | HK$1.6t | HK$1.4t | HK$25.1b | 12.4x | 61.9x | 1.1x |
| Mon, 07 Aug 2023 | HK$1.7t | HK$1.3t | HK$14.1b | 14.8x | 118.4x | 1.2x |
| Wed, 05 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.5b | 13.9x | 695.4x | 1.3x |
| Fri, 02 Jun 2023 | HK$1.7t | HK$1.3t | HK$3.2b | 13.9x | 537.8x | 1.3x |
| Sun, 30 Apr 2023 | HK$1.9t | HK$1.4t | HK$4.6b | 16.4x | 417.3x | 1.4x |
| Tue, 28 Mar 2023 | HK$1.9t | HK$1.4t | HK$410.2m | 15.5x | 4553.2x | 1.4x |
| Thu, 23 Feb 2023 | HK$2.0t | HK$1.3t | HK$2.0b | 15.8x | 977.1x | 1.4x |
| Sat, 21 Jan 2023 | HK$2.1t | HK$1.4t | HK$2.2b | 15.8x | 935x | 1.5x |
| Mon, 19 Dec 2022 | HK$1.9t | HK$1.3t | HK$2.1b | 14.2x | 875.3x | 1.4x |
| Wed, 16 Nov 2022 | HK$1.8t | HK$1.3t | HK$1.1b | 13.6x | 1731.7x | 1.4x |
| Fri, 14 Oct 2022 | HK$1.4t | HK$1.3t | HK$2.6b | 12.7x | 554.1x | 1.1x |
| Sun, 11 Sep 2022 | HK$1.7t | HK$1.3t | HK$3.2b | 14.3x | 535.4x | 1.3x |
| Tue, 09 Aug 2022 | HK$1.8t | HK$1.3t | -HK$966,498,139.00 | 13.6x | -1878.2x | 1.4x |
| Thu, 07 Jul 2022 | HK$2.0t | HK$1.3t | -HK$1,057,073,541.00 | 15.1x | -1897.1x | 1.5x |
| Sat, 04 Jun 2022 | HK$1.6t | HK$1.3t | -HK$2,376,937,222.00 | 13.2x | -685.2x | 1.2x |
| Mon, 02 May 2022 | HK$1.7t | HK$1.3t | -HK$2,054,351,924.00 | 14x | -808.3x | 1.3x |
| Wed, 30 Mar 2022 | HK$1.8t | HK$1.3t | HK$6.3b | 14x | 283x | 1.3x |
| Fri, 25 Feb 2022 | HK$1.9t | HK$1.3t | HK$8.7b | 13.8x | 223.2x | 1.4x |
| Sun, 23 Jan 2022 | HK$2.3t | HK$1.3t | HK$7.9b | 15.6x | 285.9x | 1.7x |
| Tue, 21 Dec 2021 | HK$2.2t | HK$1.3t | HK$8.0b | 13.9x | 279.6x | 1.7x |
| Thu, 18 Nov 2021 | HK$2.7t | HK$1.3t | HK$8.0b | 15.5x | 337.5x | 2x |
| Sat, 16 Oct 2021 | HK$2.6t | HK$1.3t | HK$7.8b | 15.4x | 337.2x | 2x |
| Mon, 13 Sep 2021 | HK$2.8t | HK$1.3t | HK$7.8b | 16.9x | 362.5x | 2.2x |
| Wed, 11 Aug 2021 | HK$3.2t | HK$1.3t | HK$7.5b | 17.8x | 425.5x | 2.5x |
| Sun, 06 Jun 2021 | HK$3.8t | HK$1.2t | -HK$1,960,161,127.54 | 21.1x | -1923.3x | 3.1x |
Price to Earnings Ratio
-1923.3x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 45.0x which is lower than its 3-year average PE of 122x.
- The 3-year average PS ratio of 1.5x is higher than the industry's current PS ratio of 0.91x.
Past Earnings Growth
- Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 5.4% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | -2.07% | |
| Healthcare | -5.87% | |
| Pharma | -2.19% | |
| Healthcare Services | -2.90% | |
| Healthtech | -3.97% | |
| Medical Equipment | -8.10% | |
| Biotech | -10.47% | |
| Life Sciences | -10.93% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 137x.
- Analysts are expecting annual earnings growth of 40.1%, which is higher than its past year's earnings decline of 23.1% per year.
Forecasted Growth
- Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 40% over the next 5 years.
- This is better than its past earnings decline of 23% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 12% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1093 CSPC Pharmaceutical Group | HK$6.83 | 6.1% +HK$4.6b | 2.1% | PE12.4x | |
| 2276 Shanghai Conant Optical | HK$10.50 | 17.1% +HK$652.7m | 98.1% | PE12.7x | |
| 512 Grand Pharmaceutical Group | HK$4.95 | 2.9% +HK$490.3m | -1.4% | PE9.2x | |
| 867 China Medical System Holdings | HK$6.94 | 2.5% +HK$414.7m | -38.3% | PE6.5x | |
| 2509 Qyuns Therapeutics | HK$28.95 | 5.3% +HK$322.0m | n/a | PS404.2x |